Clinical Trials Logo

Erosive Esophagitis clinical trials

View clinical trials related to Erosive Esophagitis.

Filter by:

NCT ID: NCT03943992 Completed - Erosive Esophagitis Clinical Trials

Clinical Trial to Assess the Efficacy and Safety of YYD601 in the Treatment of Esophageal Reflux Disease (ERD)

Start date: January 29, 2019
Phase: Phase 3
Study type: Interventional

A randomized, double-blind, double-dummy, active comparator, multi-centers, non-inferiority design clinical trial to assess the efficacy and safety of YYD601 in ERD patients (phase 3).

NCT ID: NCT03736369 Completed - Erosive Esophagitis Clinical Trials

Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Erosive Gastroesophageal Reflux Disease (Phase 3)

Start date: December 13, 2018
Phase: Phase 3
Study type: Interventional

The purpose of study is to confirm the efficacy of DWP14012 Xmg, Once daily, compared to esomeprazole 40mg in patients with erosive gastroesophageal reflux disease.

NCT ID: NCT03228407 Recruiting - Barrett Esophagus Clinical Trials

Confocal Endomicroscopy for Permeability of Esophageal Wall in Refractory Gastroesophageal Reflux Disease (GERD)

Start date: April 28, 2017
Phase: N/A
Study type: Interventional

Confocal Endomicroscopy for Permeability of Esophageal Wall in Refractory Gastroesophageal Reflux Disease (GERD)

NCT ID: NCT03006874 Completed - Erosive Esophagitis Clinical Trials

Study to Confirm the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

Start date: May 2, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to confirm the efficacy of CJ-12420, Once daily (QD), compared to esomeprazole in patients with erosive esophagitis classified as Los Angeles (LA) classification grades A to D at Week 8.

NCT ID: NCT02995239 Completed - Erosive Esophagitis Clinical Trials

A Study to Compare the Pharmacokinetic Characteristics of CJ-12420

Start date: April 2015
Phase: Phase 1
Study type: Interventional

To compare the pharmacokinetics after administration of different formulation of CJ-12420

NCT ID: NCT02873702 Terminated - Erosive Esophagitis Clinical Trials

Efficacy and Safety of Dexlansoprazole in Healing and Maintaining Healing of Erosive Esophagitis

Start date: December 21, 2016
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine the efficacy of dexlansoprazole compared to lansoprazole in healing erosive esophagitis (EE) in Chinese participants.

NCT ID: NCT02679508 Completed - Erosive Esophagitis Clinical Trials

Vonoprazan Study in Patients With Erosive Esophagitis to Evaluate Long-term Safety

Start date: March 20, 2016
Phase: Phase 4
Study type: Interventional

The purpose of this study is exploratorily evaluate the effect on gastric mucosal tissue and the safety of long-term administration (260 weeks: 5 years) of vonoprazan 10 mg or 20 mg in patients receiving maintenance treatment after healed erosive esophagitis (EE), and the curative effect of vonoprazan 20 mg versus lansoprazole in patients with EE.

NCT ID: NCT02615184 Recruiting - Erosive Esophagitis Clinical Trials

A Study of Dexlansoprazole in Healing and Maintenance of Healed Erosive Esophagitis (EE) in Children

Start date: May 23, 2023
Phase: Phase 2
Study type: Interventional

The main aims of the study are to check the - side effects and effectiveness of Dexlansoprazole in healing erosive esophagitis (EE) - side effects and effectiveness of Dexlansoprazole in maintaining healed EE in children. Participants will take Dexlansoprazole by mouth.

NCT ID: NCT02456935 Completed - Erosive Esophagitis Clinical Trials

Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis

Start date: May 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the efficacy of CJ-12420, once daily (QD), compared to esomeprazole in patients with erosive esophagitis classified as Los Angeles (LA) classification grades A to D at Week 8

NCT ID: NCT02388737 Completed - Erosive Esophagitis Clinical Trials

Efficacy and Safety of Vonoprazan Compared to Lansoprazole in the Maintenance Treatment of Erosive Esophagitis

Start date: April 1, 2015
Phase: Phase 3
Study type: Interventional

This is a comparative study of vonoprazan (TAK-438) (10 mg or 20 mg) in participants in whom endoscopic healing of erosive esophagitis has been confirmed with vonoprazan or adequate treatment with a proton pump inhibitor (PPI), to demonstrate the non-inferiority of vonoprazan to lansoprazole in their maintenance treatment (6 months or 24 weeks) as well as to determine the clinically recommended dose for vonoprazan for maintenance therapy in erosive esophagitis.